Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03333343
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : August 27, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 21, 2021
  Estimated Study Completion Date : May 21, 2021